CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Prevalence and Reversibility of Lung Hyperinflation in Asthma
Completed
- Conditions
- Asthma
- First Posted Date
- 2012-04-09
- Last Posted Date
- 2012-04-09
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 450
- Registration Number
- NCT01573364
- Locations
- 🇫🇷
Laboratoire Chiesi S.A., Courbevoie, France
A Study in Patients With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: Foster® NEXThaler® 100/6 µg/unit doseDrug: Seretide® Accuhaler® 250/50 µg/actuation
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 108
- Registration Number
- NCT01570478
- Locations
- 🇮🇹
Dipartimento Cardio-Polmonare - Azienda Ospedaliero-Universitaria - Padiglione Rasori, Parma, Italy
International Cross-sectional and Longitudinal Assessment on Asthma Control (Liaison)
Completed
- Conditions
- Asthma
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 8111
- Registration Number
- NCT01567280
- Locations
- 🇮🇹
Azienda Sanitaria Firenze Piero Palagi, Firenze, Italy
Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Comparator
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 281
- Registration Number
- NCT01476813
- Locations
- 🇬🇧
Medicines Evaluation Unit Ltd., Manchester, United Kingdom
Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 638
- Registration Number
- NCT01475032
- Locations
- 🇺🇦
Institute of Pediatrics, Kyiv, Ukraine
🇷🇴Spitalul Clinic Universitar de Urgenta Elias, Bucuresti, Romania
🇷🇺Moscow State Medical University, Moscow, Russian Federation
Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old
Phase 2
Completed
- Conditions
- Asthma in Children
- Interventions
- Drug: CHF 1535 50/6 NEXT DPI
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 26
- Registration Number
- NCT01468272
- Locations
- 🇩🇰
BørneAstmaKlinikken, Hans Knudsens Plads 1A,, Copenhagen,, Denmark
Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children
Phase 3
Completed
- Conditions
- Childhood Asthma
- Interventions
- Drug: beclomethasone dipropionate 50µg + formoterol fumarate 6µgDrug: CHF 1535 50/6µg
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 72
- Registration Number
- NCT01450774
- Locations
- 🇩🇰
BørneAstmaKlinikken, Copenhagen, Denmark
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: CHF 5074 1xDrug: CHF 5074 2xDrug: CHF 5074 3x
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 74
- Registration Number
- NCT01421056
- Locations
- 🇺🇸
Memory Center of New Jersey, Inc., Monroe Twp, New Jersey, United States
🇮🇹Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milano, Italy
🇺🇸Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States
Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers
Phase 1
Completed
- Conditions
- COPD
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 44
- Registration Number
- NCT01398111
- Locations
- 🇧🇪
Clinical Pharmacology Unit - SGS Life Science Services, Antwerpen, Lange Beeldekensstraat 267, Belgium
Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer Devices
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: Clenil® Modulite® via AeroChamber Plus™Drug: Clenil® Modulite® administered via Volumatic™ spacer plus charcoal blockDrug: Clenil® Modulite® via Volumatic™ spacerDrug: Clenil® Modulite® via AeroChamber Plus™ plus charcoal block
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 16
- Registration Number
- NCT01370031
- Locations
- 🇬🇧
Medicines Evaluation Unit, Wythenshawe Hospital, Manchester, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath